Amy Baker Mandragouras

Practice Areas

Amy Baker Mandragouras provides strategic counseling to life sciences companies in developing and implementing intellectual property strategies and building strong global patent portfolios to protect and facilitate commercialization of biopharmaceuticals. Her clients range from entrepreneurs and startups to leading pharmaceutical and biotechnology companies. She works closely with clients to understand their competitive landscape and is adept at assessing the strengths and weaknesses of patent portfolios.

Amy advises on patentability, validity and freedom-to-operate issues and develops effective offensive and defensive patent strategies. She has extensive IP due diligence experience and regularly advises on the patent and intellectual property aspects of biotechnology and pharmaceutical collaborations, acquisitions, licensing deals, financing transactions and securities offerings.

Amy has experience in a wide range of life sciences subjects with a particular focus on biochemistry, cellular and molecular biology and immunology. She has over 30 years of experience obtaining patent protection for a variety of biopharmaceuticals including cell-based therapies, genome-editing therapies, interfering RNA, mRNA therapeutics, monoclonal antibodies, protein therapeutics, tissue engineering and vaccines. Her intellectual property strategies are designed to protect each stage of a product's life cycle.

Amy is recognized as one of the top life sciences patent lawyers in the US by several prominent legal directories and publications such as LMG Life Sciences, Managing Intellectual Property, Best Lawyers and Super Lawyers. She is also named among the “Top 250 Women in IP” by Managing Intellectual Property. In addition, Amy is an elected member of the Fellows of the American Bar Foundation, a global honorary society of attorneys, judges, law faculty and legal scholars.

Among her career accomplishments, Amy obtained issuance of patents for Wyeth and petitioned the USPTO seeking additional patent term adjustment (PTA) which led to a decision by the Federal Circuit in Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010) correcting the length of PTA granted to patentees due to USPTO delays in examination. As a result of this decision, many issued patents were positively impacted by providing a longer period of PTA.

Amy continually champions gender diversity in patent law through proactive hiring, training, and mentoring of women. She served on the inaugural WBA’s Women’s Leadership Initiative Task Force, and recently joined the Advisory Board of WEST Women in the Enterprise of Science and Technology.